Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
Anti-cancer immunotherapies, particularly immune checkpoint inhibitors, have significantly advanced oncology treatments but are associated with rare, potentially severe cardiotoxicities. Despite their success, these therapies are associated with immune-related adverse events including rare but sever...
Saved in:
Main Authors: | Wu Helena T., Hsu Vanessa, Win Shwe, Xing Yan |
---|---|
Format: | Article |
Language: | English |
Published: |
EDP Sciences
2025-01-01
|
Series: | Visualized Cancer Medicine |
Subjects: | |
Online Access: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20240019/vcm20240019.html |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01) -
Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations
by: Sophia Kreft, et al.
Published: (2025-01-01) -
Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01) -
Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01) -
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)